{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:52:29Z","timestamp":1781639549460,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Congenital antithrombin deficiency (CAD) is a serious inherited thrombophilia, classified as a rare disease. According to a study measuring antithrombin (AT) activity in the general Japanese population, approximately one in 650 people (0.15%) have AT deficiency. Deep vein thrombosis of the lower limbs is the most common clinical symptom. Pregnancy further increases the risk of venous thromboembolism in thrombophilia carriers. Recombinant human AT gamma (rhAT-gamma) is marketed for the treatment of thrombophilia due to CAD; however, no clinical trials for Japanese CAD patients have been conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post-marketing surveillance was conducted at 22 sites in Japan from April 2016 to March 2022 to evaluate the safety and effectiveness of rhAT-gamma under clinical use conditions in CAD patients. Patients who had received rhAT-gamma for thrombophilia due to CAD were enrolled. The observation period for each patient was 12\u2009months after treatment initiation or 28\u2009days after the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 28 patients were recruited. Of these, 22 patients (1 man, 21 women) comprised the safety and effectiveness population. The reasons for rhAT-gamma use overlapped, being surgery in 13.6% (3\/22) of the patients, pregnancy in 86.4% (19\/22), and others in 22.7% (5\/22). rhAT-gamma was administered at 20\u201394 IU\/kg once daily. In the safety evaluation, adverse events (AEs) and adverse drug reactions were observed in 31.8% (7\/22) and 18.2% (4\/22) of the patients, respectively. Serious AEs occurred in 9.1% (2\/22) of the patients; no AEs resulted in death. In the effectiveness evaluation, rhAT-gamma was judged effective in all patients. AT activity increased in most patients, contributing to safe delivery outcomes in pregnant women. Although the data were limited, D-dimer levels decreased after rhAT-gamma administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>rhAT-gamma was safe and tolerable in Japanese CAD patients, with an increase in AT activity confirmed in most patients. Among pregnant women with a higher risk of thrombosis, no thrombosis was observed before or after delivery, leading to safe childbirth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>University Hospital Medical Information Network; study ID, UMIN000050276; date of registration, 8 February 2023 (retrospectively registered).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-026-00844-x","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:35:28Z","timestamp":1772188528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A post-marketing surveillance study on the safety and effectiveness of recombinant antithrombin gamma in patients with congenital antithrombin deficiency in Japan"],"prefix":"10.1186","volume":"24","author":[{"given":"Hidesaku","family":"Asakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuwazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","first-page":"107602962312052","DOI":"10.1177\/10760296231205279","volume":"29","author":"GM Rodgers","year":"2023","unstructured":"Rodgers GM, Mahajerin A. Antithrombin therapy: current state and future outlook. Clin Appl Thromb Hemost. 2023;29:10760296231205279. https:\/\/doi.org\/10.1177\/10760296231205279.","journal-title":"Clin Appl Thromb Hemost"},{"key":"844_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1538-7836.2004.00603.x","volume":"2","author":"T Sakata","year":"2004","unstructured":"Sakata T, Okamoto A, Mannami T, Matsuo H, Miyata T. Protein C and antithrombin deficiency are important risk factors for deep vein thrombosis in Japanese. J Thromb Haemost. 2004;2:528\u201330. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00603.x.","journal-title":"J Thromb Haemost"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1365-2516.2008.01830.x","volume":"14","author":"MM Patnaik","year":"2008","unstructured":"Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14:1229\u201339. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01830.x.","journal-title":"Haemophilia"},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1538-7836.2005.01197.x","volume":"3","author":"CY Vossen","year":"2005","unstructured":"Vossen CY, Conard J, Fontcuberta J, Makris M, VAN Der Meer FJ, Pabinger I, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. European prospective cohort on thrombophilia (EPCOT). J Thromb Haemost. 2005;3:459\u201364. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01197.x.","journal-title":"J Thromb Haemost"},{"key":"844_CR5","doi-asserted-by":"publisher","unstructured":"Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017;359:j4452. https:\/\/doi.org\/10.1136\/bmj.j4452.","DOI":"10.1136\/bmj.j4452"},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5045\/kjh.2011.46.3.148","volume":"46","author":"T Matsushita","year":"2011","unstructured":"Matsushita T. Engineered therapeutic antibodies with enhanced effector functions: clinical application of the Potelligent\u00ae technology. Korean J Hematol. 2011;46:148\u201350. https:\/\/doi.org\/10.5045\/kjh.2011.46.3.148.","journal-title":"Korean J Hematol"},{"key":"844_CR7","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1182\/blood.V91.12.4561","volume":"91","author":"T Edmunds","year":"1998","unstructured":"Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998;91:4561\u201371. https:\/\/doi.org\/10.1182\/blood.V91.12.4561","journal-title":"Blood"},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40261-019-00847-9","volume":"39","author":"H Furuie","year":"2019","unstructured":"Furuie H, Kanda H. Randomized comparison study of novel recombinant human antithrombin gamma and plasma-derived antithrombin in healthy volunteers. Clin Drug Investig. 2019;39:1185\u201394. https:\/\/doi.org\/10.1007\/s40261-019-00847-9.","journal-title":"Clin Drug Investig"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12959-024-00581-z","volume":"22","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Sugiura K, Ojima T, Serizawa M, Hirai K, Morishita E. Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan. Thromb J. 2024;22:18. https:\/\/doi.org\/10.1186\/s12959-024-00581-z.","journal-title":"Thromb J"},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/01.atv.16.6.742","volume":"16","author":"I Pabinger","year":"1996","unstructured":"Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur thrombose- und hamostaseforschung (GTH) study group on natural inhibitors. Arterioscler Thromb Vasc Biol. 1996;16:742\u201348. https:\/\/doi.org\/10.1161\/01.atv.16.6.742.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"844_CR11","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2016-03-703728","volume":"128","author":"A Gerhardt","year":"2016","unstructured":"Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood. 2016;128:2343\u201349. https:\/\/doi.org\/10.1182\/blood-2016-03-703728.","journal-title":"Blood"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1111\/jog.14879","volume":"47","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Morishita E, Tsuda H, Neki R, Kojima T, Ohga S, et al. Clinical guidance for peripartum management of patients with hereditary thrombophilia. J Obstet Gynaecol Res. 2021;47:3008\u201333. https:\/\/doi.org\/10.1111\/jog.14879.","journal-title":"J Obstet Gynaecol Res"},{"key":"844_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1160\/TH13-01-0077","volume":"110","author":"K Bramham","year":"2013","unstructured":"Bramham K, Retter A, Robinson SE, Mitchell M, Moore GW, Hunt BJ. How I treat heterozygous hereditary antithrombin deficiency in pregnancy. Thromb Haemost. 2013;110:550\u201359. https:\/\/doi.org\/10.1160\/TH13-01-0077.","journal-title":"Thromb Haemost"},{"key":"844_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00277-013-1892-0","volume":"93","author":"N Rogenhofer","year":"2014","unstructured":"Rogenhofer N, Bohlmann MK, Beuter-Winkler P, W\u00fcrfel W, Rank A, Thaler CJ, et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol. 2014;93:385\u201392. https:\/\/doi.org\/10.1007\/s00277-013-1892-0.","journal-title":"Ann Hematol"},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1160\/TH12-09-0663","volume":"109","author":"MN Di Minno","year":"2013","unstructured":"Di Minno MN, Dentali F, Veglia F, Russolillo A, Tremoli E, Ageno W. Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study. Thromb Haemost. 2013;109:167\u201369. https:\/\/doi.org\/10.1160\/TH12-09-0663.","journal-title":"Thromb Haemost"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40560-018-0339-z","volume":"6","author":"S Endo","year":"2018","unstructured":"Endo S, Shimazaki R. Antithrombin gamma study group. An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome. J Intensive Care. 2018;6:75. https:\/\/doi.org\/10.1186\/s40560-018-0339-z.","journal-title":"J Intensive Care"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00844-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:01:00Z","timestamp":1781636460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00844-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00844-x","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (ACOA 02 version 1.3, registered 18 January 2021) was reviewed and approved by the Research Ethics Review Committee of Kyowa Kirin Co., Ltd. This study was registered with the University Hospital Medical Information Network (UMIN000050276). The present study was conducted in compliance with Good Post-marketing Study Practice and with the ordinance of the Ministry of Health, Labour and Welfare No. 171, which requires neither acquisition of informed consent from patients nor ethics committee approval at participating sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HA has received consulting fees from Kyowa Kirin Co., Ltd. SI, YK and HK are employees of Kyowa Kirin Co., Ltd. MI and MF are former employees of Kyowa Kirin Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}